Trillium Therapeutics Inc. (NASDAQ:TRIL) could be one of the worst stocks that investors may not want to consider for their portfolio today as the company shares are trading 4.82% or 0.12 points down from last closing price of $2.49, reaching $2.37 at last check. Any clue why there is so much of action in the TRIL stock? The share price has dropped in 5 of the last 5 days and is up 789.29% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -2,538,844 shares, and in total 622756 shares valued at $1.476 million were seen changing hands compared with 3.162 million shares valued at $7.872 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the TRIL stock is near its bottom.
Trillium Therapeutics Inc. (TRIL) shares have notched a 3-month gain of about 789.29%, but has still advanced 141.75% year to date. By comparison, the stock added 49.1% over the past 12 months, while it jumped 349.54% over the 1 month. The company’s market cap is around $69.82M, with its short interest ratio standing at 0.11%.
In the current trading session for TRIL, the stock witnessed two major price actions, it rose to a high of $2.46 and was down as much as $2.3 at one point. The high recorded is very low when compared to their 52-week high which is $0.24. The 52-week high is now at -39.64 distance from current price. Their recent low of $3.9 represents a 878.75% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for TRIL is $11.02, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
TRIL‘s last price was up 380.74% as compared to the average trading price of 50 days recorded at $0.49 while enlarging the period to 200 trading days, the average closing price was $0.76. At present, there are 28.04 million in the total number of common shares owned by the public and among those 21.61 million shares have been available to trade. The percentage of shares being held by the company management was 0.2% while institutions stake was 32.28%. The company has generated negative returns on equity over the last 12 months (0%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the TRIL stock, there is another set of technicals that should be looked into and considered. Its 67.81% gain from moving average of $1.41 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Trillium Therapeutics Inc. — 1 analysts rate the stock as a buy with another 0 rating it strong buy. There are 1 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $4 on shares of Trillium Therapeutics Inc. (NASDAQ:TRIL), which corresponds to 68.78% upside potential than its current market price of $2.37 and implies potential despite the recent drop in the price. However, their current target price has fallen from $4 a month ago and is down handily from the consensus target of $4 a quarter ago.